Therefore, BCR-ABL blocks TXNIP transactivation by disrupting a Miz-1-p300 complex via c-Myc induction, which was compromised in CML cells with imatinib treatment. This evidence concerns the gene EP300 and chronic myelogenous leukemia, BCR-ABL1 positive.